APA (7th ed.) Citation

Weller, M., & Wick, W. (2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. The lancet. Oncology, 18(10), . https://doi.org/10.1016/S1470-2045(17)30517-X

Chicago Style (17th ed.) Citation

Weller, Michael, and Wolfgang Wick. "Rindopepimut with Temozolomide for Patients with Newly Diagnosed, EGFRvIII-expressing Glioblastoma (ACT IV): A Randomised, Double-blind, International Phase 3 Trial." The Lancet. Oncology 18, no. 10 (2017). https://doi.org/10.1016/S1470-2045(17)30517-X.

MLA (9th ed.) Citation

Weller, Michael, and Wolfgang Wick. "Rindopepimut with Temozolomide for Patients with Newly Diagnosed, EGFRvIII-expressing Glioblastoma (ACT IV): A Randomised, Double-blind, International Phase 3 Trial." The Lancet. Oncology, vol. 18, no. 10, 2017, https://doi.org/10.1016/S1470-2045(17)30517-X.